Earlier this year, the Mumbai-based drug major had signed a non-exclusive voluntary licensing agreement with MSD to manufacture and supply ...

The recommendations have been sent to the Drug Controller General of India (DCGI), which will soon decide on their approval, people in the ...

Merck's drug, molnupiravir, developed with Ridgeback Biotherapeutics, was shown to reduce hospitalizations and deaths by around 30% in a cl...

The analysis of latest data on efficacy is much less than the previous interim analysis announced by the company which was based on data fr...

The drugmaker released interim data in October showing a roughly 50% reduction in hospitalizations and deaths in 775 patients. The updated ...

The firms whose applications that will be taken up are Dr Reddy's Laboratories which has filed for approval in a consortium with five other...

The MHRA recommended the use of Covid-19 drug molnupiravir as soon as possible following a positive Covid-19 test and within five days of s...

The risk factors include obesity, older age (>60 years), diabetes mellitus, or heart disease. MHRA recommended the use of Molnupiravir as s...

The meeting between Modi and the American business magnate, whose foundation is focusing on fighting the pandemic, took place after the for...

Natco has conducted Phase III trials of molnupiravir and submitted the trial results to the drug regulator this month. "We have submitted p...

WHO assistant director said that the organisation expects to receive clarifications from Bharat Biotech by the end of this week on its COVI...

Under the terms of the agreement, MPP will be permitted to further license non-exclusive sub-licences to manufacturers and diversify the ma...

The Indian bulk drugs manufacturer joins Divi's Laboratories Ltd as an API maker for Merck's experimental oral drug. Merck has separately e...

The trials show that the pill halved the chances of hospitalisation in Covid-19 patients with mild or moderate form of the disease.

The development comes close on the heels of findings announced by the researchers that Molnupiravir was found effective for treating the pa...

In January, Merck halted work on two Covid vaccine candidates but has pressed on with research into two products to treat the disease, incl...

It also announced a partnership with privately-held Ridgeback Biotherapeutics to develop an experimental oral antiviral drug against COVID-...